Alaunos Therapeutics (NASDAQ:TCRT) Issues Quarterly Earnings Results, Beats Expectations By $1.74 EPS

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) released its earnings results on Monday. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($2.05) by $1.74, FiscalAI reports.

Alaunos Therapeutics Price Performance

TCRT stock traded down $0.03 during mid-day trading on Monday, reaching $1.60. 61,107 shares of the company’s stock were exchanged, compared to its average volume of 2,209,315. Alaunos Therapeutics has a 12-month low of $0.72 and a 12-month high of $4.50. The company has a market cap of $5.30 million, a price-to-earnings ratio of -0.84 and a beta of -1.02. The stock’s 50 day moving average is $1.64 and its 200 day moving average is $2.28.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on TCRT shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alaunos Therapeutics in a research note on Friday. TD Cowen initiated coverage on shares of Alaunos Therapeutics in a research report on Friday. They set a “buy” rating for the company. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold”.

Check Out Our Latest Stock Report on Alaunos Therapeutics

About Alaunos Therapeutics

(Get Free Report)

Alaunos Therapeutics was a biotechnology company focused on developing engineered T-cell therapies for cancer. Its research centered on T-cell receptor (TCR) therapies designed to help a patient’s immune cells recognize and attack tumors. The company’s main program investigated genetically modified T cells targeting cancer-associated mutations, including mutations in the KRAS gene, in patients with solid tumors. Its approach used a library of TCRs intended to recognize different tumor mutations.

Recommended Stories

Earnings History for Alaunos Therapeutics (NASDAQ:TCRT)

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.